IBD Non-Drug Treatments: Why FMT Leads in UC, Not Crohn’s

Fecal microbiota transplantation (FMT) has the best microbiome-therapy record for active ulcerative colitis, but that result does not carry over to Crohn's disease. Meanwhile, a broader analysis of non-drug IBD treatments ranked acupuncture/moxibustion first for inducing remission and diet first for maintenance. Those findings are not mutually exclusive. They answer different questions, in different treatment pools, with different mixes of ulcerative colitis (UC) and Crohn's disease (CD).

The useful conclusion is more specific than "one non-drug therapy wins." For active UC, combined colonoscopy-plus-enema FMT led the microbiome category across clinical and endoscopic outcomes. For CD, no microbiome-targeted formulation significantly beat placebo in the same analysis. Diet may help as part of IBD care, especially in selected settings, but its category-level ranking comes with low-certainty underlying evidence. Acupuncture/moxibustion deserves attention, not a promotion to first-line treatment, after one pooled network meta-analysis.

Two rankings, two questions

A 2025 network meta-analysis by Zhang et al. examined 38 randomized controlled trials of microbiome-targeted therapies: FMT, probiotics, prebiotics, synbiotics, and related approaches. Network meta-analysis can compare treatments that were not all tested head-to-head by combining direct and indirect trial evidence. The authors used a random-effects model and pooled relative risks with 95% confidence intervals.

Within that microbiome-focused network, FMT delivered by colonoscopy plus enema ranked highest for UC clinical response, clinical remission, and endoscopic remission. It was the only microbiome protocol that significantly outperformed placebo across all three active-UC endpoints. That makes it the category leader for UC induction, not a universal winner for every form of IBD.

A separate 2025 network meta-analysis by Jia et al. asked a broader question: how do non-pharmacological therapies compare across IBD? It included dietary interventions, FMT, exercise, mind-body approaches, acupuncture/moxibustion (APMX), and combinations. The review was registered in PROSPERO, searched databases through November 2024, and required included trials to have Jadad scores above 3. In this larger, pooled UC-and-CD comparison, APMX ranked first for remission induction. Dietary interventions ranked first for remission maintenance and fecal calprotectin reduction, while FMT ranked second.

A ranking is not a treatment recommendation by itself. SUCRA rankings estimate the probability that an intervention sits near the top of a network; they do not provide an absolute remission rate, prove a clinically large effect, or erase weaknesses in the studies being pooled.

Why FMT can lead in UC and fall in a broader IBD analysis

The most important split is disease-specific. Zhang et al. found no microbiome-targeted therapy that significantly outperformed placebo in the CD subgroup. Synbiotics combining Bifidobacterium with fructooligosaccharides or inulin, and Saccharomyces boulardii preparations, ranked relatively highly but did not reach statistical significance.

That null result helps explain why FMT falls behind APMX in Jia et al.'s pooled analysis. A treatment with a favorable UC signal will lose ground when the analysis also includes CD, where that signal does not appear. The pooled result cannot establish that APMX beats combined-route FMT for UC specifically, because it does not make that like-for-like, disease-stratified comparison.

Biology offers a plausible explanation, though it does not prove one. UC primarily affects the colonic mucosa, where a delivered microbial community may have more direct access to diseased tissue. CD often affects the ileum or ileocolonic segments and can involve transmural inflammation. In a 2021 cohort study by Boland et al., CD patients with mucosal healing and persistent diarrhea had lower intestinal microbial diversity and greater dysbiosis than comparison groups. The study analyzed 590 tissue biopsy specimens from 215 patients with IBD and 48 healthy controls. It shows an association between persistent symptoms and microbiome features after healing; it does not prove that dysbiosis causes failed FMT or that restoring diversity would treat CD.

Probiotics have a narrower UC signal

Zhang et al. ranked multistrain probiotics containing specified Lactobacillus and Bifidobacterium genera second overall in UC. These products significantly improved UC endoscopic remission and relapse prevention. That is a meaningful distinction from a vague "probiotics help IBD" claim: the reported benefits applied to particular UC endpoints, not to every symptom, every strain, or CD.

The practical problem is specificity. The analysis does not identify the individual strains, colony-forming-unit doses, treatment durations, or commercial products that produced the signal. A label that says "contains probiotics" is not evidence that it matches the trial interventions. Patients considering a product should review it with an IBD clinician rather than treating the category name as a prescription.

Prebiotics ranked first numerically for relapse prevention in the same analysis, but did not significantly beat placebo. Numerical rank without statistical significance is a lead worth studying, not proof of benefit.

Diet is active treatment—but the hierarchy is unfinished

Dietary interventions are more than generic advice to eat well. A 2025 systematic review by Gleave et al. describes specific carbohydrate, Mediterranean, anti-inflammatory, and exclusive enteral nutrition (EEN) approaches as protocols studied for IBD outcomes. Jia et al.'s finding that dietary interventions ranked first for maintenance and fecal calprotectin reduction fits with that broader clinical interest.

Still, the diet result is category-level. It does not tell a reader whether a Mediterranean diet beats a specific-carbohydrate diet, whether either matches EEN, or how long adherence must last. A 2024 umbrella review by Christensen et al. judged most dietary-intervention evidence low quality and highly uncertain. Differences in diet definitions, adherence, comparators, and endpoints make a clean winner hard to name.

EEN is the clearest example of both promise and limits. A 2023 pediatric CD study by Ding et al. reported remission-induction rates of 57% to 84% with EEN in children with Crohn's disease and examined microbiota signatures and mucosal healing against corticosteroid treatment. Those results do not automatically apply to adults, for whom adherence is harder and efficacy is less certain. Formula replacement is also a very different intervention from adding a probiotic to breakfast.

APMX is a real signal with unanswered questions

APMX's first-place induction rank in Jia et al.'s analysis should not be waved away. The review used an explicit protocol and a higher-Jadad trial threshold. But no independent Cochrane review in this evidence base confirms APMX as an IBD remission-induction treatment, and the available report does not establish how well sham controls worked across the acupuncture trials. Blinding is difficult when participants can often tell whether they received a procedure.

Nor are the reported SUCRA uncertainty intervals or sensitivity analyses excluding high-risk-of-bias trials available here. Those details matter because rankings can change when a small set of biased or imprecise studies is removed. APMX is a reasonable research signal; it is not a reason to reorganize medical treatment around needles or moxibustion.

What this means for people with UC or CD

For active UC, combined colonoscopy-plus-enema FMT has the strongest microbiome-therapy evidence in this group of studies. Yet the protocol remains investigational or available mainly through specialist programs in many health systems. Commercial microbiota products, where available, are generally intended for recurrent C. difficile infection rather than UC. FMT for UC should therefore be pursued, if at all, with an IBD specialist or through an appropriate clinical trial—not through improvised donor stool experiments. The latter is less biohacking than microbiological roulette.

For UC maintenance, multistrain Lactobacillus-Bifidobacterium probiotics have a more accessible but less precisely translatable evidence signal. Diet can be a useful adjunct, but no current evidence here justifies declaring one named diet the best for all patients.

For CD, the evidence supports more restraint. Zhang et al. found no significant placebo-beating microbiome therapy, and a 2021 Cochrane review by Sinopoulou et al. found no strong evidence that non-pharmacological interventions reliably managed abdominal pain in CD or IBD. Its endpoint was symptom management rather than remission maintenance, so it does not directly overturn Jia et al.'s maintenance ranking. It does reinforce the broader point that a pooled IBD ranking should not be treated as proof of a CD-specific treatment effect.

For UC, the best-supported non-drug microbiome option is specialist-delivered combined-route FMT for induction. For CD, non-drug measures belong alongside evidence-based medical care, not in place of it.

The evidence does not offer a single non-drug champion for IBD. It offers a more useful map: FMT leads its category in UC; probiotics have selected UC maintenance outcomes; diet remains plausible but uncertain as a ranked category; and APMX needs disease-specific confirmation. That map is less tidy than a winner's podium, but it is closer to the data.